Immunomedics Inc

Immunomedics Inc is a biopharmaceutical company that specializes in developing innovative therapies for cancer and other serious diseases. Their lead product candidate, sacituzumab govitecan, is a novel antibody-drug conjugate that targets the TROP-2 receptor, overexpressed in many solid tumors. Immunomedics is also developing other antibody-drug conjugates and bi-specific antibodies for cancer and autoimmune diseases. Their mission is to improve patients' lives by commercializing innovative therapies that address unmet medical needs. Headquartered in Morris Plains, New Jersey, Immunomedics operates in the US and Europe.